mp.weixin.qq.com·· 3 hours agoScore76
ESMO 2026 Presents Six Mirvetuximab Soravtansine Studies Spanning Platinum-Resistant First-Line, Platinum-Sensitive Combinations and Chinese Real-World Data
In brief
The 2026 ESMO congress includes six mirvetuximab soravtansine (MIRV) abstracts, covering a post hoc analysis of first-line therapy and responders in FRα-positive platinum-resistant ovarian cancer, long-term follow-up from Chinese real-world data, pretreatment albumin as a predictor, the FLORENZA combination regimen, and hematologic safety of carboplatin combination in platinum-sensitive ovarian cancer.
Source: mp.weixin.qq.com · mp.weixin.qq.com